<DOC>
	<DOCNO>NCT02531906</DOCNO>
	<brief_summary>This randomize pilot clinical trial study side effect gabapentin well work give together methadone hydrochloride oxycodone hydrochloride improve quality life patient stage II-IV head neck cancer chemoradiation . Gabapentin , methadone hydrochloride , oxycodone hydrochloride may help relieve moderate severe pain cause head neck cancer chemoradiation therapy .</brief_summary>
	<brief_title>Gabapentin , Methadone Hydrochloride , Oxycodone Hydrochloride Improving Quality Life Patients With Stage II-IV Head Neck Cancer During Chemoradiation</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Collect preliminary data safety efficacy two analgesic regimen use design large study compare regimen . SECONDARY OBJECTIVES : I . Examine effect treatment regimens pain control , oral mucositis , quality-of-life rating score chemoradiation therapy ( CRT ) . TERTIARY OBJECTIVES : I . To assess treatment regimen effect patient nutrition hydration status CRT ( weight loss , vitals , oral [ PO ] tolerance , etc. ) . OUTLINE : Patients randomize 1 2 arm . ARM I : Patients receive gabapentin PO thrice daily ( TID ) 7 week radiotherapy . ARM II : Patients receive gabapentin PO TID , methadone hydrochloride PO twice daily ( BID ) , oxycodone hydrochloride PO every 8 hour ( Q8H ) need ( PRN ) 7 week radiotherapy . All patient may continue receive treatment pain throughout course chemoradiation therapy ( 24 month follow CRT continue pain regimen ) . After completion study , patient follow 30 day , 3 , 6 , 9 , 12 month . Patients require prolonged analgesic therapy may follow every 6 month 24 month .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Patients eligible chemoradiation therapy head neck Baseline creatinine ( Cr ) great 1.5 time upper limit normal Have clinical stage IIIV head neck carcinoma Have pathologic diagnosis squamous cell carcinoma head neck region Have Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Ability swallow retain oral medication take feeding tube Patients childbearing potential must agree use adequate contraceptive method ( e.g. , hormonal barrier method birth control ; abstinence ) prior study entry ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately Patient legal representative must understand investigational nature study sign Independent Ethics Committee/Institutional Review Board approve write informed consent form prior receive study related procedure Patients previously treat surgery radiation head neck cancer and/or treat recurrent head neck cancer Patients know brain metastasis exclude clinical trial Any patient prescribed medication chronic pain and/or neuropathy exclude , include patient treatment pain specialist substanceabuse program Uncontrolled concurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant nursing female patient Unwilling unable follow protocol requirement Any condition Investigator 's opinion deem patient unsuitable candidate receive study drug Received investigational agent within 30 day prior enrollment Patients medication prolong QT interval Patients dialysis transplant organs Patients already enrolled study systemic pain control agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>